We have shown that loss of autophagy through ATG5 inhibits tumor growth in a cell-autonomous fashion in inflammation-driven (AOM/DSS), sporadic (Apc), and patient-derived in vitro models of CRC. Here, ATG5 is linked to colorectal carcinoma.